Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from the Global Open-Label Extension (OLE) study of ONPATTRO® (patisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults, at the European Academy of Neurology (EAN) Virtual Congress. In addition, interim results were presented from a Phase 3b trial evaluating treatment with patisiran in patients with hATTR amyloidosis with disease progression after receiving an orthotopic liver transplant (post-OLT).
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2020 and reviewed recent business highlights.
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
Alnylam Pharmaceuticals (NASDAQ: ALNY) has been a phenomenal biotech stock. The company had its initial public offering in 2004. Shares are now 22 times more valuable than they were 16 years ago. That's an incredible stock performance.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
Alnylam (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Alnylam (ALNY) loss narrows in Q1. It beats sales estimates but cuts guidance for product revenues from Onpattro due to potential impact of COVID-19.
Alnylam (ALNY) delivered earnings and revenue surprises of 14.29% and 9.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The partners will develop VIR-2703, which has the potential to prevent COVID-19, and also to treat it.
Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
SAN FRANCISCO, May 12, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.
ALNY earnings call for the period ending March 31, 2020.
Q1 2020 Alnylam Pharmaceuticals Inc Earnings Call
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1). The FDA also granted Priority Review for the NDA, a designation for medicines that have the potential to provide significant improvements in the treatment, prevention or diagnosis of a serious disease, with the goal of FDA taking action within six months compared to 10 months under standard review.
The impact of the pandemic led the biopharmaceutical company to trim its revenue guidance for polyneuropathy treatment Onpattro.
Alnylam (ALNY) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is (ALNY) Outperforming Other Medical Stocks This Year?
Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.